Retatrutide vs. Mounjaro: Is the "Triple-Action" jab worth the wait?
How this compares with treatments available today
Patients are increasingly asking how Retatrutide compares with Mounjaro and whether waiting for a triple-action option is worthwhile. Retatrutide is still investigational, while Mounjaro is already licensed and available in UK clinical practice. This guide compares how they work, what current trial data suggests, and why sourcing unapproved products online is unsafe.
Retatrutide vs Mounjaro™: Quick comparison
| Feature | Retatrutide Injection | Mounjaro™ Injection |
|---|---|---|
| Active ingredient | Retatrutide. | Tirzepatide. |
| Mechanism of action | Triple GIP, GLP-1, and glucagon receptor agonist. | Dual GIP and GLP-1 receptor agonist. |
| Frequency | Once weekly. | Once weekly. |
| Administration | Subcutaneous (under the skin). | Subcutaneous (under the skin). |
| Dosing options | 1 mg, 2 mg, 4 mg, 8 mg, and 12 mg (based on clinical trials). | 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. |
| Storage | Refrigerated (long-term). | Refrigerated (long-term). |
| Clinical weight loss | Approximately 24.2% to 28.7% (average in clinical trials). | Approximately 15% to 22.5% (average). |
| Approval status | Investigational (currently undergoing clinical trials). | Approved. |
What is Retatrutide?
Retatrutide (LY3437943) is a cutting-edge weight-loss drug currently under development by Eli Lilly and Company, the same manufacturer behind medications like Mounjaro. Unlike existing GLP-1 medications such as semaglutide (Wegovy) or tirzepatide (Mounjaro), Retatrutide is a triple agonist—targeting GLP-1, GIP, and glucagon receptors simultaneously. This multi-receptor action is what makes it so promising for treating obesity and type 2 diabetes.
How does Retatrutide work?
Retatrutide’s mode of action targets three metabolic pathways:
- GLP-1 receptor activation: Helps control blood sugar, reduces appetite, and slows stomach emptying.
- GIP receptor activation: Enhances insulin response and supports the utilisation of fat stores in adipose tissue for energy.
- Glucagon receptor activation: Increases energy expenditure and promotes fat burning.
By activating all three, Retatrutide offers a novel approach to weight management by helping patients eat less, burn more, and improve their metabolic health.
What do studies show about Retatrutide?
Currently, Retatrutide is in Phase III clinical trials, which began in late 2023 and are expected to conclude in 2026. In Phase II trials, the results were groundbreaking:
- Participants on the highest dose lost up to 24% of their body weight in 48 weeks.
- Even at 24 weeks, average weight loss reached 17.5%—far exceeding most current treatments.
These results have led some experts to call Retatrutide the “next-generation weight-loss drug” and even a potential “game-changer” in obesity treatment.
When might Retatrutide become available?
If Phase 3 trials remain positive, Eli Lilly may apply for regulatory approval in 2026 or later.
Why buying Retatrutide online can be risky
With all the hype surrounding Retatrutide, some people are already trying to buy it through online vendors, social media, or black-market suppliers. This is extremely dangerous for several reasons:
- No quality control: Unapproved versions may contain incorrect doses, harmful substances, or no active ingredient at all.
- No medical supervision: Using a powerful hormone-based drug without proper guidance can lead to severe side effects such as nausea, pancreatitis, or dangerous blood sugar drops.
- Legal risks: Purchasing unlicensed medications is illegal and can lead to serious consequences.
Counterfeit versions pose significant dangers because they bypass the rigorous approval processes that ensure drug are safe, pure, and work. Simply put, If it’s not coming from a regulated pharmacy or clinical trial, it’s not safe.
